Google
Apple
English (UK)
English (Canada)
Deutsch (Deutschland)
Deutsch (Schweiz)
Español
Français (France)
Italiano
Nederlands (Nederland)
Nederlands (België)
GSK PLC |
Market Closed -
Other stock markets
|
|
5-day change | 1st Jan Change | |
| 1,411.80 GBX | -0.17% | -0.40% | -1.79% | |
| Nov. 28 | Pfizer disappointed in RSV shot's market share, CFO says | RE |
| Nov. 28 | Novartis Touts R&D Pipeline Progress, Upgraded Midterm Targets as Pure-play Medicines Company | MT |
Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Exceptional extension!
Enjoy this offer
* See conditions on site
| Sales 2023 * | 29.61 B 37.60 B | Sales 2024 * | 31.15 B 39.56 B | Capitalization | 57.26 B 72.71 B |
|---|---|---|---|---|---|
| Net income 2023 * | 5,490 M 6,971 M | Net income 2024 * | 5,641 M 7,162 M | EV / Sales 2023 * | 2,44x |
| Net Debt 2023 * | 14.89 B 18.91 B | Net Debt 2024 * | 12.08 B 15.33 B | EV / Sales 2024 * | 2,23x |
| P/E ratio 2023 * | 10,4x | P/E ratio 2024 * | 10,1x | Employees | 69,400 |
| Yield 2023 * | 4,04% | Yield 2024 * | 4,36% | Free-Float | 93.29% |
More Fundamentals
* Assessed data
More news
More press releases
More news
| 1 day | -0.17% | ||
| 1 week | +0.27% | ||
| Current month | -3.13% | ||
| 1 month | -1.49% | ||
| 3 months | +2.75% | ||
| 6 months | +1.41% | ||
| Current year | -1.79% |
1 week
1 372.60
1 430.00
1 month
1 371.401 513.20
Current year
1 302.601 563.20
1 year
1 302.601 609.00
3 years
1 280.923 408.16
5 years
1 280.923 408.16
10 years
1 280.923 408.16
| Managers | Title | Age | Since |
|---|---|---|---|
Emma Walmsley
CEO | Chief Executive Officer | 54 | 2010 |
| Chief Tech/Sci/R&D Officer | - | 2017 | |
Tony Wood
CTO | Chief Tech/Sci/R&D Officer | - | 2017 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Jonathan Symonds
CHM | Chairman | 65 | 2019 |
Urs Rohner
BRD | Director/Board Member | 64 | 2014 |
Hal Barron
BRD | Director/Board Member | 61 | 2017 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 10.37% | 19 M€ | -0.52% | ||
| 10.37% | 5 M€ | -4.87% | - | |
| 5.80% | 34 M€ | -2.64% | - | |
| 5.80% | 106 M€ | +0.47% | ||
| 5.07% | 982 M€ | +1.61% |
| Date | Price | Change | Volume |
|---|---|---|---|
| 23-11-28 | 1,411.80 | -0.17% | 5,168,417 |
| 23-11-27 | 1,414.20 | -0.59% | 2,685,048 |
| 23-11-24 | 1,422.60 | +0.11% | 4,716,875 |
| 23-11-23 | 1,421.00 | +0.69% | 4,771,854 |
| 23-11-22 | 1,411.20 | -0.44% | 10,825,050 |
Delayed Quote London Stock Exchange, November 28, 2023 at 11:35 am EST
More quotes
GSK plc is a global biopharma company. The Companyâs segments include Commercial Operations and Research and Development. It develops cancer medicines for patients, including ovarian cancer, endometrial cancer, and multiple myeloma. It has developed monoclonal antibodies to help treat different diseases. Its product areas include vaccines, specialty medicines, and general medicine. Its vaccine portfolio includes more than 20 vaccines that help protect people from a range of diseases and infections throughout their lives. Its specialty medicines include medicines for immune-mediated conditions. Its specialty medicines are also engaged in developing medicines for respiratory disease and HIV. Its general medicines include inhaled medicines for asthma and chronic obstructive pulmonary disease (COPD), antibiotics, and medicines for skin diseases. The Company owns camlipixant, a selective P2X3 antagonist, which is in Phase III development for the treatment of refractory chronic cough (RCC).
Sector
Pharmaceuticals
Calendar
04:00am
- The Redburn CEO Conference
Trading Rating :
Investor Rating :
ESG Refinitiv :
B
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
22
Last Close Price
14.12GBP
Average target price
17.25GBP
Spread / Average Target
+22.16%
EPS Revisions
| 1st Jan change | Capi. (M$) | |
|---|---|---|
| -1.79% | 72 325 M $ | |
| +61.71% | 532 B $ | |
| +46.67% | 464 B $ | |
| -14.16% | 364 B $ | |
| -14.56% | 246 B $ | |
| -18.80% | 216 B $ | |
| +2.02% | 201 B $ | |
| -11.75% | 195 B $ | |
| -42.06% | 170 B $ | |
| +1.10% | 141 B $ |